title: Medical management of brain tumors and the sequelae of treatment.
abstract: Patients with malignant brain tumors are prone to complications that negatively impact their quality of life and sometimes their overall survival as well. Tumors may directly provoke seizures, hypercoagulable states with resultant venous thromboembolism, and mood and cognitive disorders. Antitumor treatments and supportive therapies also produce side effects. In this review, we discuss major aspects of supportive care for patients with malignant brain tumors, with particular attention to management of seizures, venous thromboembolism, corticosteroids and their complications, chemotherapy including bevacizumab, and fatigue, mood, and cognitive dysfunction.
authors.affiliation: Neuro-Oncology Center, University of Virginia Medical Center, Charlottesville, Virginia (D.S.); Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts (E.Q.L., L.N., A.D.N., D.A.R., P.Y.W.).
authors.forename: David
authors.initials: D
authors.lastname: Schiff
authors.affiliation: Neuro-Oncology Center, University of Virginia Medical Center, Charlottesville, Virginia (D.S.); Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts (E.Q.L., L.N., A.D.N., D.A.R., P.Y.W.).
authors.forename: Eudocia Q
authors.initials: EQ
authors.lastname: Lee
authors.affiliation: Neuro-Oncology Center, University of Virginia Medical Center, Charlottesville, Virginia (D.S.); Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts (E.Q.L., L.N., A.D.N., D.A.R., P.Y.W.).
authors.forename: Lakshmi
authors.initials: L
authors.lastname: Nayak
authors.affiliation: Neuro-Oncology Center, University of Virginia Medical Center, Charlottesville, Virginia (D.S.); Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts (E.Q.L., L.N., A.D.N., D.A.R., P.Y.W.).
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Norden
authors.affiliation: Neuro-Oncology Center, University of Virginia Medical Center, Charlottesville, Virginia (D.S.); Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts (E.Q.L., L.N., A.D.N., D.A.R., P.Y.W.).
authors.forename: David A
authors.initials: DA
authors.lastname: Reardon
authors.affiliation: Neuro-Oncology Center, University of Virginia Medical Center, Charlottesville, Virginia (D.S.); Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts (E.Q.L., L.N., A.D.N., D.A.R., P.Y.W.).
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000150:complications* / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions; D005221:Fatigue / Q000150:complications / Q000188:drug therapy; D006801:Humans; D010166:Palliative Care; D012307:Risk Factors; D012640:Seizures / Q000150:complications / Q000188:drug therapy; D054556:Venous Thromboembolism / Q000150:complications / Q000188:drug therapy
chemical_list: D000305:Adrenal Cortex Hormones; D000927:Anticonvulsants
keywords: bevacizumab; brain tumor; chemotherapy; cognition; complications; corticosteroids; fatigue; mood; seizure; symptom management; vasogenic edema; venous thromboembolism